Does the media favor PRQR or DRUG?

In the previous week, Bright Minds Biosciences had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 2 mentions for ProQR Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.68 beat ProQR Therapeutics' score of 0.51 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRQR or PHAR?

In the previous week, Pharming Group had 8 more articles in the media than ProQR Therapeutics. MarketBeat recorded 10 mentions for Pharming Group and 2 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat Pharming Group's score of 0.35 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PRQR or RIGL?

In the previous week, Rigel Pharmaceuticals had 24 more articles in the media than ProQR Therapeutics. MarketBeat recorded 26 mentions for Rigel Pharmaceuticals and 2 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat Rigel Pharmaceuticals' score of 0.27 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor PRQR or CLYM?

In the previous week, Climb Bio had 14 more articles in the media than ProQR Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 2 mentions for ProQR Therapeutics. Climb Bio's average media sentiment score of 0.61 beat ProQR Therapeutics' score of 0.51 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ProQR Therapeutics (PRQR) Competitors

$1.88 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.88 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Compare

PRQR vs. DRUG, PHAR, RIGL, CLYM, and BBOT

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include Bright Minds Biosciences (DRUG), Pharming Group (PHAR), Rigel Pharmaceuticals (RIGL), Climb Bio (CLYM), and BridgeBio Oncology Therapeutics (BBOT). These companies are all part of the "biotechnology" industry.

How does ProQR Therapeutics compare to Bright Minds Biosciences?

ProQR Therapeutics (NASDAQ:PRQR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

ProQR Therapeutics currently has a consensus price target of $7.33, indicating a potential upside of 291.11%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 81.31%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, meaning that its stock price is 627% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Bright Minds Biosciences' return on equity of -20.58% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Bright Minds Biosciences has lower revenue, but higher earnings than ProQR Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.98	-$47.73M	-$0.50	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

In the previous week, Bright Minds Biosciences had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 2 mentions for ProQR Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.68 beat ProQR Therapeutics' score of 0.51 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Bright Minds Biosciences beats ProQR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Pharming Group?

ProQR Therapeutics (NASDAQ:PRQR) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pharming Group has a net margin of 2.51% compared to ProQR Therapeutics' net margin of -331.33%. Pharming Group's return on equity of 3.40% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Pharming Group	2.51%	3.40%	1.90%

Pharming Group has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.98	-$47.73M	-$0.50	N/A
Pharming Group	$376.13M	2.04	$2.85M	$0.12	90.42

In the previous week, Pharming Group had 8 more articles in the media than ProQR Therapeutics. MarketBeat recorded 10 mentions for Pharming Group and 2 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat Pharming Group's score of 0.35 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

ProQR Therapeutics presently has a consensus target price of $7.33, suggesting a potential upside of 291.11%. Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 256.37%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

ProQR Therapeutics and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Rigel Pharmaceuticals?

ProQR Therapeutics (NASDAQ:PRQR) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Rigel Pharmaceuticals has a net margin of 116.30% compared to ProQR Therapeutics' net margin of -331.33%. Rigel Pharmaceuticals' return on equity of 22.95% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

ProQR Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 291.11%. Rigel Pharmaceuticals has a consensus price target of $54.50, indicating a potential upside of 35.67%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rigel Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 24 more articles in the media than ProQR Therapeutics. MarketBeat recorded 26 mentions for Rigel Pharmaceuticals and 2 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat Rigel Pharmaceuticals' score of 0.27 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.98	-$47.73M	-$0.50	N/A
Rigel Pharmaceuticals	$294.28M	2.53	$367.02M	$16.32	2.46

Summary

Rigel Pharmaceuticals beats ProQR Therapeutics on 11 of the 14 factors compared between the two stocks.

How does ProQR Therapeutics compare to Climb Bio?

ProQR Therapeutics (NASDAQ:PRQR) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Climb Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Climb Bio's return on equity of -31.79% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Climb Bio	N/A	-31.79%	-30.79%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 14 more articles in the media than ProQR Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 2 mentions for ProQR Therapeutics. Climb Bio's average media sentiment score of 0.61 beat ProQR Therapeutics' score of 0.51 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 291.11%. Climb Bio has a consensus target price of $22.75, indicating a potential upside of 62.50%. Given ProQR Therapeutics' higher probable upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

ProQR Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.98	-$47.73M	-$0.50	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Summary

Climb Bio beats ProQR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to BridgeBio Oncology Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 2 mentions for ProQR Therapeutics and 0 mentions for BridgeBio Oncology Therapeutics. ProQR Therapeutics' average media sentiment score of 0.51 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ProQR Therapeutics	Positive
BridgeBio Oncology Therapeutics	Neutral

ProQR Therapeutics has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.98	-$47.73M	-$0.50	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

ProQR Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 291.11%. BridgeBio Oncology Therapeutics has a consensus price target of $24.80, suggesting a potential upside of 165.81%. Given ProQR Therapeutics' higher probable upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

BridgeBio Oncology Therapeutics beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$197.55M	$3.69B	$7.02B	$13.01B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.75	9.02	270.57	25.03
Price / Sales	10.98	1,297.99	599.88	84.35
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	3.54	17.61	11.21	6.43
Net Income	-$47.73M	-$13.25M	$3.45B	$348.10M
7 Day Performance	9.65%	4.99%	3.41%	2.68%
1 Month Performance	8.38%	-2.13%	-0.71%	-0.83%
1 Year Performance	-13.59%	61.28%	77.31%	23.97%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	3.837 of 5 stars	$1.88 flat	$7.33 +291.1%	-13.6%	$197.55M	$17.99M	N/A	180	Positive News Gap Up
DRUG Bright Minds Biosciences	2.5713 of 5 stars	$77.35 +4.8%	$143.83 +86.0%	+104.4%	$718.04M	N/A	N/A	N/A	Upcoming Earnings
PHAR Pharming Group	3.739 of 5 stars	$10.26 +4.5%	$38.67 +276.9%	-18.0%	$695.04M	$376.13M	85.50	280	Gap Up
RIGL Rigel Pharmaceuticals	4.2859 of 5 stars	$38.70 +3.4%	$54.50 +40.8%	+26.7%	$692.53M	$294.28M	2.07	160	News Coverage Earnings Report Analyst Forecast Analyst Revision
CLYM Climb Bio	2.4284 of 5 stars	$12.56 +6.4%	$22.08 +75.8%	+723.5%	$676.28M	N/A	N/A	9	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. DRUG, PHAR, RIGL, CLYM, and BBOT

How does ProQR Therapeutics compare to Bright Minds Biosciences?

Summary

How does ProQR Therapeutics compare to Pharming Group?

Summary

How does ProQR Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Summary

How does ProQR Therapeutics compare to BridgeBio Oncology Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. DRUG, PHAR, RIGL, CLYM, and BBOT

How does ProQR Therapeutics compare to Bright Minds Biosciences?

Do analysts prefer PRQR or DRUG?

Which has more risk and volatility, PRQR or DRUG?

Is PRQR or DRUG more profitable?

Which has better valuation and earnings, PRQR or DRUG?

Does the media favor PRQR or DRUG?

Do insiders & institutionals have more ownership in PRQR or DRUG?

Summary

How does ProQR Therapeutics compare to Pharming Group?

Do insiders and institutionals have more ownership in PRQR or PHAR?

Is PRQR or PHAR more profitable?

Which has higher earnings & valuation, PRQR or PHAR?

Does the media favor PRQR or PHAR?

Which has more volatility and risk, PRQR or PHAR?

Do analysts prefer PRQR or PHAR?

Summary

How does ProQR Therapeutics compare to Rigel Pharmaceuticals?

Is PRQR or RIGL more profitable?

Do analysts prefer PRQR or RIGL?

Which has more volatility & risk, PRQR or RIGL?

Does the media prefer PRQR or RIGL?

Do insiders & institutionals believe in PRQR or RIGL?

Which has higher earnings & valuation, PRQR or RIGL?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Is PRQR or CLYM more profitable?

Do institutionals and insiders have more ownership in PRQR or CLYM?

Does the media favor PRQR or CLYM?

Do analysts recommend PRQR or CLYM?

Which has stronger earnings & valuation, PRQR or CLYM?

Which has more risk & volatility, PRQR or CLYM?

Summary

How does ProQR Therapeutics compare to BridgeBio Oncology Therapeutics?

Do insiders and institutionals hold more shares of PRQR or BBOT?

Is PRQR or BBOT more profitable?

Which has more volatility & risk, PRQR or BBOT?

Does the media favor PRQR or BBOT?

Which has stronger earnings and valuation, PRQR or BBOT?

Do analysts recommend PRQR or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools